What Does Big Pharma Think About Patient Centricity?
At the 2018 Financial Times Pharmaceutical and Biotechnology Conference, there was a lot of buzz around ‘patient centricity’ and all of the big pharma companies were determined to broadcast their…
Brian Hilberdink, President of Novo Nordisk Canada, calls for collaboration between government and industry to ensure that Canadian patients get swift access to the best treatments. As a Canadian who spent several years working globally for a biopharmaceutical company, I…
At the 2018 Financial Times Pharmaceutical and Biotechnology Conference, there was a lot of buzz around ‘patient centricity’ and all of the big pharma companies were determined to broadcast their…
There are around 2 billion people in the world that do not have access to the medicines they need. This week the 2018 Access to Medicine Index was published revealing…
Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the United States, discusses the contradictory nature of Trump’s efforts to lower drug prices. …
Stanimir Hasurdjiev explains the key role of the National Patients’ Organization (NPO) in Bulgaria and discusses the main areas that he is working on to ensure that patients are heard and can benefit from the best treatments and care available at a reasonable price. You are working in different organizations besides the National Patients’ Organization. Can you explain how…
Mayra Galindo Leal, general director of the Mexican Association of the Fight Against Cancer (AMLCC) provides an overview of the main milestones of this association that stands as the most…
Antonio Bernal, president of the General Patient Alliance (AGP), discusses the role of the patient voice in the Spanish healthcare system and how the alliance is the bridge between the…
The global pharma industry is facing increased pressure to ensure lifesaving medications reach underserved populations. Drawing from a new Access to Medicine Foundation report, AMF Head of Research Claudia Martinez…
Patients and carers with lived experience of a disease have valuable insights to share with physicians and drug developers alike. This is especially true of rare diseases, defined in the…
In the October 2024 edition of DIA’s Global Forum magazine, Global Forum founding Editor-in-Chief and former DIA board member Andrzej Czarnecki of Eli Lilly and Company shares his reflections on…
The Promising Pathways Act 2.0 is a newly proposed bill that aims to expedite and streamline approval pathways for rare disease therapies in the US. The Act is, however, facing…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Drawing on her experience as rare disease patient advocacy group SYNGAP1 Foundation’s founder and former president, Monica Weldon argues for the need to standardize genomic testing practices, warns against the…
See our Cookie Privacy Policy Here
